PL2563400T3 - Modified binding proteins inhibiting the VEGF-A receptor interaction - Google Patents

Modified binding proteins inhibiting the VEGF-A receptor interaction

Info

Publication number
PL2563400T3
PL2563400T3 PL11716429T PL11716429T PL2563400T3 PL 2563400 T3 PL2563400 T3 PL 2563400T3 PL 11716429 T PL11716429 T PL 11716429T PL 11716429 T PL11716429 T PL 11716429T PL 2563400 T3 PL2563400 T3 PL 2563400T3
Authority
PL
Poland
Prior art keywords
vegf
binding proteins
receptor interaction
modified binding
proteins inhibiting
Prior art date
Application number
PL11716429T
Other languages
Polish (pl)
Inventor
Hans Kaspar Binz
Patrik Forrer
Michael Tobias Stumpp
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of PL2563400T3 publication Critical patent/PL2563400T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11716429T 2010-04-30 2011-04-29 Modified binding proteins inhibiting the VEGF-A receptor interaction PL2563400T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10161685 2010-04-30
EP11716429.3A EP2563400B1 (en) 2010-04-30 2011-04-29 Modified binding proteins inhibiting the VEGF-A receptor interaction
PCT/EP2011/056824 WO2011135067A1 (en) 2010-04-30 2011-04-29 Modified binding proteins inhibiting the vegf-a receptor interaction

Publications (1)

Publication Number Publication Date
PL2563400T3 true PL2563400T3 (en) 2020-02-28

Family

ID=42313869

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11716429T PL2563400T3 (en) 2010-04-30 2011-04-29 Modified binding proteins inhibiting the VEGF-A receptor interaction

Country Status (34)

Country Link
US (5) US8710187B2 (en)
EP (2) EP2563400B1 (en)
JP (1) JP6010528B2 (en)
KR (1) KR101680064B1 (en)
CN (1) CN103002920B (en)
AR (1) AR081361A1 (en)
AU (1) AU2011247563B2 (en)
BR (1) BR112012027368B1 (en)
CA (1) CA2797996C (en)
CL (1) CL2012003025A1 (en)
CO (1) CO6640296A2 (en)
CY (1) CY1122107T1 (en)
DK (1) DK2563400T3 (en)
ES (1) ES2745491T3 (en)
HR (1) HRP20191660T1 (en)
HU (1) HUE045272T2 (en)
IL (1) IL222749B (en)
LT (1) LT2563400T (en)
ME (1) ME03559B (en)
MX (1) MX347535B (en)
MY (1) MY162564A (en)
NZ (1) NZ602943A (en)
PH (1) PH12012502115A1 (en)
PL (1) PL2563400T3 (en)
PT (1) PT2563400T (en)
RS (1) RS59408B1 (en)
RU (1) RU2605309C2 (en)
SG (1) SG185068A1 (en)
SI (1) SI2563400T1 (en)
SM (1) SMT201900553T1 (en)
TW (1) TWI510246B (en)
UA (1) UA111820C2 (en)
WO (1) WO2011135067A1 (en)
ZA (1) ZA201207594B (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
TWI510246B (en) 2010-04-30 2015-12-01 Molecular Partners Ag Modified binding proteins inhibiting the vegf-a receptor interaction
DK2643349T3 (en) 2010-11-26 2019-11-25 Molecular Partners Ag DESIGNED REPEAT PROTEINS BINDING TO SERUM ALBUMIN
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint, Inc. Methods for treating Vascular Leak Syndrome and cancer
HUE046134T2 (en) 2012-05-07 2020-02-28 Allergan Inc Method of treating amd in patients refractory to anti-vegf therapy
LT3679922T (en) 2012-06-01 2021-10-25 Novartis Ag Syringe
CA2877584A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
DE202013000688U1 (en) 2012-07-03 2013-03-05 Novartis Ag Glass syringe
AU2012101678B4 (en) 2012-07-03 2013-01-24 Novartis Ag Use of device
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
US11453708B2 (en) 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
JP2016522248A (en) 2013-06-20 2016-07-28 ノバルティス アーゲー Treatment of polypoidal choroidal vasculopathy
JP2016522249A (en) 2013-06-20 2016-07-28 ノバルティス アーゲー Use of VEGF antagonists in the treatment of choroidal neovascularization
WO2014203183A1 (en) 2013-06-20 2014-12-24 Novartis Ag Use of a vegf antagonist in treating macular edema
EP3019527A2 (en) 2013-07-11 2016-05-18 Novartis AG Use of a vegf antagonist in treating retinopathy of prematurity
KR20160029794A (en) 2013-07-11 2016-03-15 노파르티스 아게 Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
AU2014286996A1 (en) 2013-07-12 2016-01-07 Iveric Bio, Inc. Methods for treating or preventing ophthalmological conditions
CA2927012A1 (en) * 2013-11-05 2015-05-14 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin
CN105026433B (en) * 2014-01-24 2018-10-19 上海恒瑞医药有限公司 VEGF and PDGFR β bispecific fusion proteins and application thereof
US9388239B2 (en) * 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
RU2702748C2 (en) 2014-05-12 2019-10-11 Формикон Аг Pre-filled plastic syringe containing vegf antagonist
KR20160075107A (en) * 2014-12-19 2016-06-29 주식회사 이노테라피 PEGylated VEGF-Trap and Method for Preparation Thereof
AU2016240220B2 (en) 2015-04-02 2019-11-21 Molecular Partners Ag Designed ankyrin repeat domains with binding specificity for serum albumin
KR101676690B1 (en) 2015-08-04 2016-11-16 (주) 에빅스젠 Tetrapeptide having effect of inhibiting VEGF-induced angiogenesis and use thereof
WO2018218013A2 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
CA3005132A1 (en) 2015-11-18 2017-05-26 Sio2 Medical Products, Inc. Coated syringe for ophthalmic formulations containing a vegf antagonist
WO2017087798A1 (en) 2015-11-18 2017-05-26 Formycon Ag Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
CN108290004A (en) 2015-11-18 2018-07-17 福尔密孔股份公司 Prefilled plastic syringes containing VEGF antagonists
AU2017213103B2 (en) 2016-01-26 2022-08-11 Formycon Ag Liquid formulation of a VEGF antagonist
CN109073660B (en) 2016-02-29 2022-10-28 麦恩泰科特有限公司 Predictive markers useful for the treatment of wet age-related macular degeneration
AU2017299581B2 (en) 2016-07-20 2024-05-23 EyePoint, Inc. Humanized monoclonal antibodies that target ve-ptp (hptp-β)
US10717772B2 (en) 2016-09-22 2020-07-21 Molecular Partners Ag Recombinant binding proteins targeting HER2 and serum albumin, and their uses
CN108623694B (en) * 2017-03-24 2021-09-17 北京市肿瘤防治研究所 Derivative of vascular endothelial cell growth factor receptor antagonistic peptide F56 and application thereof
WO2018217995A1 (en) 2017-05-24 2018-11-29 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag Liquid formulation of a vegf antagonist
CN120058958A (en) * 2018-09-24 2025-05-30 视点制药公司 Multispecific antibodies targeting HPTP-beta (VE-PTP) and VEGF
CN114206943A (en) 2019-06-04 2022-03-18 分子伴侣公司 Multispecific proteins
KR20220113492A (en) 2019-12-11 2022-08-12 몰리큘라 파트너스 아게 Designed ankyrin repeat domains with altered surface residues
KR20230006558A (en) 2020-05-06 2023-01-10 몰리큘라 파트너스 아게 Novel ankyrin repeat binding proteins and uses thereof
IL298168A (en) 2020-05-14 2023-01-01 Molecular Partners Ag Multispecific proteins
CA3202358A1 (en) 2020-12-16 2022-06-23 Andreas BOSSHART Novel slow-release prodrugs
CN112961250B (en) * 2021-03-01 2023-06-06 长春金赛药业有限责任公司 Antibody fusion proteins and uses thereof
WO2022190010A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd33 engagers
AU2022233791A1 (en) 2021-03-09 2023-09-28 Molecular Partners Ag Novel darpin based cd123 engagers
JP2024509890A (en) 2021-03-09 2024-03-05 モレキュラー パートナーズ アクチェンゲゼルシャフト Protease cleavable prodrugs
IL305677A (en) 2021-03-09 2023-11-01 Molecular Partners Ag A new derpin based on multispecific T-cell phases
BR112023022439A2 (en) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc IMPLANTABLE DEVICE FOR SUSTAINED RELEASE OF A MACROMOLECULAR DRUG COMPOUND
IL313411A (en) 2021-12-14 2024-08-01 Molecular Partners Ag Designed repeat regions with dual binding specificity and their use
JP2025527242A (en) 2022-08-01 2025-08-20 モレキュラー パートナーズ アクチェンゲゼルシャフト Charge-engineered engineered repeat domains and their uses
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
EP4673159A1 (en) 2023-02-27 2026-01-07 Molecular Partners AG Darpins for use in reducing renal accumulation of drugs
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
WO2025163082A1 (en) 2024-01-31 2025-08-07 Molecular Partners Ag Dll3-specific binding constructs and their use in radiotherapy
WO2026055147A1 (en) * 2024-09-03 2026-03-12 Gdm Holding Llc High-affinity protein binders and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
DE69735292T2 (en) 1996-10-25 2006-10-19 Gilead Sciences, Inc., Foster City GEFAESSZELLEN GROWTH FACTOR (VEGF) NUCLEINE ACID ELEMENT COMPLEXES
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
EP2338915A3 (en) 1997-04-07 2011-10-12 Genentech, Inc. Anti-VEGF antibodies
JP3957765B2 (en) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド Anti-VEGF antibody
DE69834032T2 (en) 1997-04-23 2006-12-07 Universität Zürich METHOD OF DETECTING NUCLEIC ACID MOLECULES COPYING FOR (POLY) PEPTIDES THAT INTERACT WITH TARGET MOLECULES
DE69935248T2 (en) 1998-12-02 2007-11-08 Adnexus Therapeutics, Inc., Waltham DNA PROTEIN FUSIONS AND APPLICATIONS THEREOF
ATE303400T1 (en) * 1999-04-02 2005-09-15 Ajinomoto Kk METHOD FOR PRODUCING PEPTIDE SUBUNITS FROM POLYMER PROTEINS
CN100523187C (en) * 1999-06-08 2009-08-05 里珍纳龙药品有限公司 Modified chimeric polypeptides with improved pharmacokinetic properties
DE60140474D1 (en) 2000-09-08 2009-12-24 Univ Zuerich COLLECTION OF PROTEINS WITH REPEATED SEQUENCES (REPEAT PROTEINS) CONTAINING REPETITIVE SEQUENCE MODULES
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EA012622B1 (en) * 2004-06-01 2009-10-30 Домэнтис Лимитед Bispecific fusion antibodies with enhanced serum half-life
WO2006137938A2 (en) * 2004-11-08 2006-12-28 The University Of Texas At Austin Antibody fragments for protection from pathogen infection and methods of use thereof
BRPI0517834A (en) * 2004-11-12 2008-10-21 Bayer Schering Pharma Ag recombinant newcastle disease virus
DE102005002978B4 (en) * 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Recombinant expression of proteins in a disulfide-bonded, two-chain form
BRPI0613593A2 (en) 2005-07-08 2011-01-18 Univ Zuerich filamentous phage display test method, phage or phagemid vector and phage or phagemid vector library
EP1996937A4 (en) 2006-03-06 2009-04-08 Amunix Inc Genetic packages and uses thereof
EP2004693B1 (en) 2006-03-30 2012-06-06 Novartis AG Compositions and methods of use for antibodies of c-met
RU2424246C2 (en) 2006-05-26 2011-07-20 Ипсен Фарма С.А.С. Method for site-specific pegylation
US20100144599A1 (en) 2007-02-02 2010-06-10 Bristol-Myers Squibb Company Vegf pathway blockade
ATE502114T1 (en) 2007-06-21 2011-04-15 Univ Muenchen Tech BIOLOGICALLY ACTIVE PROTEINS WITH INCREASED IN-VIVO AND/OR IN-VITRO STABILITY
CA2700391A1 (en) 2007-09-24 2009-04-02 University Of Zuerich Designed armadillo repeat proteins
EP3785735A1 (en) * 2008-11-03 2021-03-03 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
TWI510246B (en) * 2010-04-30 2015-12-01 Molecular Partners Ag Modified binding proteins inhibiting the vegf-a receptor interaction
DK2643349T3 (en) 2010-11-26 2019-11-25 Molecular Partners Ag DESIGNED REPEAT PROTEINS BINDING TO SERUM ALBUMIN
EP2702069A4 (en) 2011-04-29 2015-04-29 Janssen Biotech Inc Il4/il13 binding repeat proteins and uses
CA2877584A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
WO2014019157A1 (en) 2012-08-01 2014-02-06 华为技术有限公司 Communication path processing method and apparatus
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
US11453708B2 (en) 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor

Also Published As

Publication number Publication date
US10646542B2 (en) 2020-05-12
EP2563400A1 (en) 2013-03-06
ZA201207594B (en) 2013-06-26
TWI510246B (en) 2015-12-01
BR112012027368A2 (en) 2021-06-29
IL222749A0 (en) 2012-12-31
HUE045272T2 (en) 2019-12-30
EP2563400B1 (en) 2019-07-10
MY162564A (en) 2017-06-30
CN103002920A (en) 2013-03-27
RS59408B1 (en) 2019-11-29
KR20130076821A (en) 2013-07-08
RU2605309C2 (en) 2016-12-20
US9289466B2 (en) 2016-03-22
AR081361A1 (en) 2012-08-29
AU2011247563A1 (en) 2013-01-10
CY1122107T1 (en) 2020-11-25
MX2012012638A (en) 2013-06-28
US20160263185A1 (en) 2016-09-15
PT2563400T (en) 2019-09-27
ES2745491T3 (en) 2020-03-02
HRP20191660T1 (en) 2019-12-13
US20130116197A1 (en) 2013-05-09
NZ602943A (en) 2014-07-25
SMT201900553T1 (en) 2019-11-13
US20210069293A1 (en) 2021-03-11
RU2012151205A (en) 2014-06-10
DK2563400T3 (en) 2019-09-16
US8710187B2 (en) 2014-04-29
US20140221295A1 (en) 2014-08-07
JP2013531616A (en) 2013-08-08
US9849158B2 (en) 2017-12-26
EP3593821A1 (en) 2020-01-15
KR101680064B1 (en) 2016-11-28
SI2563400T1 (en) 2019-11-29
LT2563400T (en) 2019-10-10
PH12012502115A1 (en) 2013-01-07
WO2011135067A1 (en) 2011-11-03
CN103002920B (en) 2018-03-02
SG185068A1 (en) 2012-12-28
CL2012003025A1 (en) 2013-08-23
JP6010528B2 (en) 2016-10-19
US20180125932A1 (en) 2018-05-10
IL222749B (en) 2020-08-31
CA2797996C (en) 2017-10-03
TW201141509A (en) 2011-12-01
ME03559B (en) 2020-07-20
AU2011247563B2 (en) 2014-07-10
CA2797996A1 (en) 2011-11-03
MX347535B (en) 2017-04-28
UA111820C2 (en) 2016-06-24
BR112012027368B1 (en) 2024-02-15
CO6640296A2 (en) 2013-03-22

Similar Documents

Publication Publication Date Title
IL222749A0 (en) Modified binding proteins inhibiting the vegf-a receptor interaction
IL271804A (en) Mice that make binding proteins
IL212589A0 (en) Binding proteins inhibiting the vegf-a receptor interaction
EP2555797A4 (en) Tnf- binding proteins
EP2649189A4 (en) Tnf- binding proteins
SG10201401681PA (en) Novel antigen binding proteins
ZA201300975B (en) Binding proteins for hepcidin
IL229618A0 (en) Fc receptor binding proteins
ZA201504023B (en) Bcma antigen binding proteins
IL222823A0 (en) Nuclear receptor binding agents
LT2536745T (en) Novel ctla4-ig immunoadhesins
ZA201303957B (en) Melt-blended protein composition
SG2014010334A (en) Fn14 binding proteins and uses thereof
IL226157A0 (en) Antigen binding proteins
SG10201503080XA (en) Eif4e binding peptides
GB201003906D0 (en) Binding polypeptides
GB201007550D0 (en) Modified receptor fusion proteins
GB201004150D0 (en) Modified receptor fusion proteins
GB201103961D0 (en) Binding polypeptides
TWM400980U (en) Binding
GB201010143D0 (en) Comb binding
HK1176233A (en) Nuclear receptor binding agents